Literature DB >> 3920862

Effect of ibuprofen on heterotopic ossification after hip replacement.

E Elmstedt, T S Lindholm, O S Nilsson, H Törnkvist.   

Abstract

A double-blind, placebo-controlled study was made of the influence of the anti-inflammatory agent ibuprofen on heterotopic ossification after total hip replacement for arthrosis, fracture or rheumatoid arthritis. Seven drop-outs left 21 patients on medication and 22 on placebo in two comparable groups. Heterotopic ossification appeared in one third of the patients in the ibuprofen group and in three fourths in the control group 12 months after surgery. Five patients in the latter group developed true heterotopic bone, compared to one of the patients on medication. Heterotopic ossification was as common among osteoarthritic patients as among others. There was no difference in the range of motion at 12 months postoperatively between patients with and without heterotopic ossification. In the 22 patients with heterotopic ossification this was demonstrated in all but eight within 6 weeks, and in only three did it appear later than 3 months postoperatively. Five of the six patients who showed heterotopic bone with trabecular structure were male. Since inflammation is a dominant feature in the postoperative phase, the effect of ibuprofen on heterotopic ossification is probably its inhibition of the synthesis of prostaglandins. This implies that prevention is most successful if commenced before or at the time of operation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3920862     DOI: 10.3109/17453678508992973

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  19 in total

1.  Nonsteroid anti-inflammatory drugs prevent the recurrence of heterotopic ossification after excision.

Authors:  B Sodemann; P E Persson; O S Nilsson
Journal:  Arch Orthop Trauma Surg       Date:  1990       Impact factor: 3.067

Review 2.  Role of oestrogen in the development of osteoporosis.

Authors:  T C Hillard; J C Stevenson
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

Review 3.  Heterotopic ossification: clinical and cellular aspects.

Authors:  J R Sawyer; M A Myers; R N Rosier; J E Puzas
Journal:  Calcif Tissue Int       Date:  1991-09       Impact factor: 4.333

4.  Flurbiprofen inhibits heterotopic bone formation in total hip arthroplasty.

Authors:  V Hoikka; T S Lindholm; A Eskola
Journal:  Arch Orthop Trauma Surg       Date:  1990       Impact factor: 3.067

5.  Para-articular ossification in total hip replacement: an indication for irradiation therapy.

Authors:  R Brunner; E Morscher; R Hünig
Journal:  Arch Orthop Trauma Surg       Date:  1987

Review 6.  [Value of a combined ossification prophylaxis with indomethacin and radiotherapy for acetabular fractures].

Authors:  S Piatek; T Westphal; D Arbter; S Winckler
Journal:  Unfallchirurg       Date:  2006-07       Impact factor: 1.000

7.  A comparison of indomethacin and diclofenac in the inhibition of experimental heterotopic new bone formation.

Authors:  O S Nilsson; H C Bauer; O Brosjö; H Törnkvist
Journal:  Int Orthop       Date:  1987       Impact factor: 3.075

8.  Effects of acetylsalicylic acid on heterotopic bone resorption and formation in rats.

Authors:  L F Solheim; H Rönningen; N Langeland
Journal:  Arch Orthop Trauma Surg       Date:  1986

9.  Heterotopic ossification rates after acetabular fracture surgery are unchanged without indomethacin prophylaxis.

Authors:  Sean M Griffin; Stephen H Sims; Madhav A Karunakar; Rachel Seymour; Nikkole Haines
Journal:  Clin Orthop Relat Res       Date:  2013-09       Impact factor: 4.176

Review 10.  Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach.

Authors:  F Richy; O Bruyere; O Ethgen; V Rabenda; G Bouvenot; M Audran; G Herrero-Beaumont; A Moore; R Eliakim; M Haim; J-Y Reginster
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.